Delivery Order SPE2DB22D3011-SPE2DB25FQ1DE

Award Date 6/5/25
Potential Completion Date 6/6/25
Potential Value $1.8K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XCOPRI 50 MG TABLET 30S, a pharmaceutical product, and has a ceiling value of $2,042.81. The contract is a Firm Fixed Price type and is not designated as a set-aside. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distribution company. The contract, valued at $1,768.44, is for the delivery of XCOPRI 150 MG TABLET 30S, a specialty pharmaceutical product. The contract does not have a set-aside designation, indicating it was an open competition. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,905.84, is for the delivery of XCOPRI 100 MG TABLET 30S, a pharmaceutical product. The contract has an ultimate completion date of February 20, 2025 and is a firm-fixed-price delivery order. There is no set-aside designation for this contract. AmerisourceBergen holds a significant...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XCOPRI 50 MG TABLET 30S, a pharmaceutical product, with a ceiling value of $3,952.38 and a performance period extending through May 13, 2025. The contract is a firm fixed-price delivery order, with no set-aside designation, indicating open competition. AmerisourceBergen...
This is a $1,768.44 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of XCOPRI 50 MG TABLET 30S, a medication, with a period of performance through May 16, 2025. Amerisourcebergen Drug Corp holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which provides a comprehensive global...
This is a delivery order contract awarded to AmerisourceBergen Drug Corp by the Defense Logistics Agency (DLA), a defense agency, to provide XCOPRI 100 MG tablets. The contract has a firm fixed price of $6,037.07 and a completion date of February 12, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC covers a comprehensive range of pharmaceutical...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,768.44, is for the delivery of the pharmaceutical product XCOPRI 50 MG TABLET 30S. The contract has an ultimate completion date of April 4, 2025 and is a firm fixed-price contract. This contract is not designated as a set-aside. AmerisourceBergen Drug Corp holds a significant Indefinite...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,178.96 Firm Fixed Price Delivery Order is for the supply of XCOPRI 50 MG TABLET 30S, a pharmaceutical product. The contract has an ultimate completion date of April 10, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,895.81 Firm Fixed Price Delivery Order contract is for the supply of XCOPRI 25 MG TABLET 30S, a medication, to support military healthcare programs. The contract has an ultimate completion date of April 9, 2025 and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,821.20, is for the delivery of 4567957363 ! XCOPRI 100 MG TABLET 30S, a pharmaceutical product. The contract has a firm fixed price pricing type and an ultimate completion date of April 18, 2025. This contract is not a set-aside and is an open competition award. AmerisourceBergen Drug...
  • SPE2DB22D3011
    Indefinite Delivery Contract
  • SPE2DB22D3011-SPE2DB25FQ1DE
    Delivery Order

This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of XCOPRI 25 MG TABLET 30S. The contract has a firm fixed price of $1,768.44 and a performance period ending on June 6, 2025. The contract is not set aside and is an open competition. AmerisourceBergen Drug Corp has a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which provides a comprehensive global pharmaceutical support vehicle through December 2026. This IDC allows the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, serving customers including the Defense Health Agency and the U.S. Coast Guard.

Generated 9/4/25, 9:46 AM